Abstract
One of the most important molecules mediating the proliferation, growth, and metastasis of cancer cells is insulin-like growth factor (IGF), with its receptor IGF-1R. Here, we describe the potential of an IGF-1R monoclonal antibody, HX-1162, on liver cancer apoptosis in vitro and in vivo. We found that HX-1162 could induce the apoptosis of cultured liver cancer cells. Additionally, HX-1162 treatment inhibited the tumor growth after cancer cell grafting and enhanced the cell apoptosis inside the tumor tissue. We conclude that IGF-1R targeting therapy provides a new avenue toward treating liver cancer. © 2013 Chen et al, publisher and licensee Dove Medical Press Ltd.
Author supplied keywords
Cite
CITATION STYLE
Chen, X. H., Li, Z. Q., Peng, H., Jin, S. M., Fu, H. Q., Zhu, T. C., & Weng, X. G. (2013). Type 1 insulin-like growth factor receptor monoclonal antibody (HX-1162) treatment for liver cancer. OncoTargets and Therapy, 6, 527–530. https://doi.org/10.2147/OTT.S44162
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.